Replies to post #96401 on Biotech Values

[DewDiligence]

Yes, MRK will presumably have access to the blinded anemia data from the SPRINT-2 and RESPOND-2 trials in addition to the open-label data from the anemia trial. All told, this should allow MRK to make an informed judgment about when to submit the Boceprevir NDA.